Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: Discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one

Robert Hughes(Scripps Research Institute), Ying Yu(Wuhan University), Jerry W. Cubbage(Pfizer (United States)), Alan MacInnes(Pfizer (United States)), Todd M. Maddux(Pfizer (United States)), Yi Zheng(Pfizer (United States)), Mike B. Tollefson(Pfizer (United States)), Dafydd R. Owen(Pfizer (United States)), E. Jon Jacobsen(Pfizer (United States)), D. Joseph Rogier(Pfizer (United States)), John K. Walker(Pfizer (United States)), Yvette M. Fobian(Pfizer (United States)), Rhadika M. Blevis-Bal(Pfizer (United States)), Brent V. Mischke(Pfizer (United States)), Steve E. Heasley(Pfizer (United States)), Brad A. Acker(Pfizer (United States)), Joseph B. Moon(Pfizer (United States)), David Brown(Pfizer (United States)), John M. Molyneaux(Pfizer (United States)), Jeanne M. Rumsey(Pfizer (United States)), John N. Freskos(Pfizer (United States)), Brian R. Bond(Pfizer (United States)), Alan G. Benson(Pfizer (United States))
Bioorganic & Medicinal Chemistry Letters
July 11, 2009
Cited by 15


Related Papers